Literature DB >> 25744005

Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.

Giulio Conte1, Juan Sieira2, Giuseppe Ciconte2, Carlo de Asmundis2, Gian-Battista Chierchia2, Giannis Baltogiannis2, Giacomo Di Giovanni2, Mark La Meir3, Francis Wellens3, Jens Czapla3, Kristel Wauters2, Moises Levinstein2, Yukio Saitoh2, Ghazala Irfan2, Justo Julià2, Gudrun Pappaert2, Pedro Brugada2.   

Abstract

BACKGROUND: Patients with Brugada syndrome and aborted sudden cardiac death or syncope have higher risks for ventricular arrhythmias (VAs) and should undergo implantable cardioverter-defibrillator (ICD) placement. Device-based management of asymptomatic patients is controversial. ICD therapy is associated with high rates of inappropriate shocks and device-related complications.
OBJECTIVES: The objective of this study was to investigate clinical features, management, and long-term follow-up of ICD therapy in patients with Brugada syndrome.
METHODS: Patients presenting with spontaneous or drug-induced Brugada type 1 electrocardiographic findings, who underwent ICD implantation and continuous follow-up at a single institution, were eligible for this study.
RESULTS: A total of 176 consecutive patients were included. During a mean follow-up period of 83.8 ± 57.3 months, spontaneous sustained VAs occurred in 30 patients (17%). Eight patients (4.5%) died. Appropriate ICD shocks occurred in 28 patients (15.9%), and 33 patients (18.7%) had inappropriate shocks. Electrical storm occurred in 4 subjects (2.3%). Twenty-eight patients (15.9%) experienced device-related complications. In multivariate Cox regression analysis, aborted sudden cardiac death and VA inducibility on electrophysiologic studies were independent predictors of appropriate shock occurrence.
CONCLUSIONS: ICD therapy was an effective strategy in Brugada syndrome, treating potentially lethal arrhythmias in 17% of patients during long-term follow-up. Appropriate shocks were significantly associated with the presence of aborted sudden cardiac death but also occurred in 13% of asymptomatic patients. Risk stratification by electrophysiologic study may identify asymptomatic patients at risk for arrhythmic events and could be helpful in investigating syncope not related to VAs. ICD placement is frequently associated with device-related complications, and rates of inappropriate shocks remain high regardless of careful device programming.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brugada syndrome; implantable cardioverter-defibrillator; sudden cardiac death; ventricular arrhythmias

Mesh:

Substances:

Year:  2015        PMID: 25744005     DOI: 10.1016/j.jacc.2014.12.031

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

Review 1.  The Diagnosis, Risk Stratification, and Treatment of Brugada Syndrome.

Authors:  Johannes Steinfurt; Jürgen Biermann; Christoph Bode; Katja E Odening
Journal:  Dtsch Arztebl Int       Date:  2015-06-05       Impact factor: 5.594

Review 2.  [Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].

Authors:  D Duncker; T König; S Hohmann; C Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

Review 3.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Europace       Date:  2017-04-01       Impact factor: 5.214

Review 4.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

Authors:  Charles Antzelevitch; Gan-Xin Yan; Michael J Ackerman; Martin Borggrefe; Domenico Corrado; Jihong Guo; Ihor Gussak; Can Hasdemir; Minoru Horie; Heikki Huikuri; Changsheng Ma; Hiroshi Morita; Gi-Byoung Nam; Frederic Sacher; Wataru Shimizu; Sami Viskin; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2016-07-13       Impact factor: 6.343

5.  Programmed electrical stimulation for patients with asymptomatic Brugada syndrome? The shock-filled debate continues.

Authors:  Michael J Ackerman; Christopher V DeSimone
Journal:  J Am Coll Cardiol       Date:  2015-03-10       Impact factor: 24.094

Review 6.  Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest.

Authors:  Serge Sicouri; Charles Antzelevitch
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

7.  Atrial fibrillation and risk of major arrhythmic events in Brugada syndrome: A meta-analysis.

Authors:  Jakrin Kewcharoen; Pattara Rattanawong; Chanavuth Kanitsoraphan; Raktham Mekritthikrai; Narut Prasitlumkum; Prapaipan Putthapiban; Poemlarp Mekraksakit; Robert J Pattison; Wasawat Vutthikraivit
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-07-29       Impact factor: 1.468

Review 8.  Brugada Syndrome:Risk Stratification And Management.

Authors:  Yoshifusa Aizawa
Journal:  J Atr Fibrillation       Date:  2016-10-31

Review 9.  Brugada Syndrome:Risk Stratification And Management.

Authors:  Konstantinos P Letsas; Stamatis Georgopoulos; Konstantinos Vlachos; Nikolaos Karamichalakis; Ioannis Liatakis; Panagiotis Korantzopoulos; Tong Liu; Michael Efremidis; Antonios Sideris
Journal:  J Atr Fibrillation       Date:  2016-08-31

Review 10.  Pathogenesis and management of Brugada syndrome.

Authors:  Juan Sieira; Gregory Dendramis; Pedro Brugada
Journal:  Nat Rev Cardiol       Date:  2016-09-15       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.